Straws are discrete research notes that relate to a particular aspect of the company. Grouped under #hashtags, they are ranked by votes.
A good Straw offers a clear and concise perspective on the company and its prospects.
Please visit the forums tab for general discussion.
MGC Pharma completes delivery of first major ArtemiCTM Rescue order to Swiss PharmaCan AG, drives March to record quarter for MGC’s product revenues
Key Highlights:
Master supply agreement was on 18/2/21...previously posted...
3/3/21 Swiss PharmaCan AG increases initial purchase order volume by 85% for first ArtemiCTM Rescue production batch
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02349339-6A1022883?access_token=83ff96335c2d45a094df02a206a39ff4
I remarked on 18/2 that I thought maybe a TH (trading Halt was coming) because of lack of details in MasterAgreement, esp $s for MXC...very happy to see the $s coming through
DISC: I hold
Ethics Committee Approval Granted for Phase III Clinical Trial of CimetrATM on Patients Diagnosed with COVID-19
Key Highlights:
Disc: I hold...although with the injections now being run out over the world, investors may not see the need for these trials now (or maybe only, for the moment). I think we still need all the trials we can
Master Supply & Distribution agreement signed with Swiss PharmaCan AG for exclusive worldwide1 distribution of ArtemiCTM Rescue
DISC~I Hold
Notes~ Master agreement & Annoucement not marked "Sensitive" ??
~Mentions Retail values, lacking in $'s for MXC...I see a TH coming
New In-vitro cannabinoid study on Glioblastoma treatment using proprietary nano-delivery platform to commence
Key Highlights:
~ MGC Pharma’s research program into the use of cannabinoids in the treatment of aggressive glioblastoma brain cancer has been expanded, in collaboration with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre
~ Preliminary results of MGC Pharma’s proprietary cannabinoid treatment of Glioblastoma have recently completed an independent peer review and been formally published in the MDPI (Multidisciplinary Digital Publishing Institute) Medical Journal
~ The new, expanded study will also explore the use of a nanoparticle delivery system to improve the effects of the glioblastoma treatment
~ Delivery system is similar to the nanoparticle delivery system being used successfully in MGC Pharma’s ArtemiCTM clinical trial into the treatment of COVID-19
~ In-vitro results to date show that MGC Pharma formulated cannabigerol (CBG) can eliminate therapy-resistant glioblastoma stem cells
~Successful study results would mean a key breakthrough for MGC Pharma in the treatment of aggressive brain cancers, one of its key target clinical research treatment areas – Oncology
~The new study will shortly commence recruitment of new patients with grade IV glioblastomas to be divided into subcategories to receive a personalised treatment plan
DISC: I Hold
MGC Pharma Welcomes Admission to the LSE & First Day of Trading
Key Highlights:
~Successful £6.5 million capital raising completed by way of an oversubscribed placement of 441 million ordinary shares at a price of 1.475 pence each to UK institutional funds, high net worth family office and professional investor clients of Turner Pope Investments
~ MGC Pharma becomes the first cannabis-sector company to IPO on the main market of the LSE in the UK
~ In FY2020 MGC Pharma generated revenue of AU$2.1m, delivering major revenue growth from FY2019 and a continuing upwards trend in FY2021
~ MGC Pharma’s existing products designed to meet immediate market concerns, including the two flagship phytocannabinoid-derived medicines: CannEpil® designed as a treatment for refractory epilepsy and CogniCann® designed to improve dementia and Alzheimer’s disease for patients’ quality of life
~ MGC Pharma has developed an affordable product range, its MP line, which leverages pharma-grade compounded products from high-CBD through to high-THC formulations
~ Company research is focused on treatment in three core areas: Neurology, Oncology, and Autoimmune diseases, and includes the development of ArtemiC™ for treatment of Covid-19 infected patients
~The net proceeds of the capital raise will be used to meet the costs associated with its priority clinical trials including ArtemiC™ and CannEpil®, as well as increasing distribution of the Group’s product range, general working capital and the completion of the Group’s manufacturing facilities in Malta
Disc: I hold
MGC Pharma set to become the first medicinal cannabis company to list on the London Stock Exchange
£6.5m (~A$12m) placement completed, led by UK institutional funds
Key Highlights:
• MGC Pharma is set to become the first medicinal cannabis related company to be admitted to the main market of the London Stock Exchange (LSE) through a standard listing, which is scheduled to take place on Tuesday, 9 February 2021
• MGC Pharma has secured binding commitments to raise £6.5 million (~A$12m), before costs, through a share placement to coincide with the Company’s imminent LSE listing
• Strategic placement to substantial UK institutional funds led by Premier Miton and Chelverton Asset Management, with high net worth family office and professional investor clients of London equity broker Turner Pope Investments Limited (Turner Pope)
• MGC Pharma will maintain a dual LSE and ASX listing to significantly broaden MGC Pharma’s international profile and specifically provide direct access to UK and European institutional and other investors, which aligns with the Company’s established and future European operations
• MGC Pharma set to fast-track commencement of ArtemiCTM Phase III clinical trials upon completion of the placing and LSE Listing, to be conducted across 3 continents and over 250 patients
DISC: I have small holding